摘要:
A δ-crystalline form of ivabradine hydrochloride of formula (I): characterised by its powder X-ray diffraction data.Medicinal products containing the same which are useful as bradycardics.
摘要:
A γ-Crystalline form of ivabradine hydrochloride of formula (I): characterised by its powder X-ray diffraction data.Medicinal products containing the same which are useful as bradycardics.
摘要:
A γd-Crystalline form of ivabradine hydrochloride of formula (I): characterised by its powder X-ray diffraction data. Medicinal products containing the same which are useful as bradycardics.
摘要:
A γ-Crystalline form of ivabradine hydrochloride of formula (I): characterised by its powder X-ray diffraction data. Medicinal products containing the same which are useful as bradycardics.
摘要:
A process for the industrial synthesis and new crystalline form of the compound of formula (I): Medicinal products containing the same which are useful in treating disorders of the melatoninergic system.
摘要:
A compound selected from those of formula (I): Medicinal products containing the same which are useful in the treatment of disorders of the melatoninergic system.
摘要:
The invention relates to compounds of formula (I): wherein: R1 represents hydrogen, alkyl or cycloalkyl, R2 represents hydrogen, halogen or hydroxy, A represents CR3R4 or NR3 wherein R3 and R4 are as defined in the description, Y represents an alkylene chain as described in the description, X represents NR5R6, S(O)nR7, OR8, C(O)R9, amidino or a heterocycle, their isomers, and addition salts thereof; and medicinal products containing the same which are useful in the prevention or treatment of diseases associated with AMPA flux.
摘要:
The invention relates to 1-{2(S)-[1(S)-(ethoxycarbonyl)butylamino]propionyl}-(3aS,7aS)octahydroindol-2(S)-carboxylic acid of the Formula I and the t-butylamine salt of the Formula I′ thereof free of contaminations derivable from dicyclohexyl carbodiimide, and a process for the preparation thereof. The invention also relates to new intermediates of the general Formula III (wherein R stands for lower alkyl or aryl lower alkyl). The compound of the Formula I—perindopril—is a known ACE inhibitor.
摘要:
The invention relatests compound of formula (I): wherein: n is 1, 2 or 3, A represents a group or a group X represents N or NR1, R2 represents an alkoxy, cycloalkyloxy or cycloalkylalkyloxy group. and medicinal products containing the same which are useful in treading or in preventing melatoninergic disorder.
摘要:
Compounds of formula (I): wherein: R1 represents hydroxy or RCO—O—, R2 represents hydrogen, halogen, hydroxy or R′CO—O, R, R′, which may be identical or different, represent linear or branched (C1-C6)alkyl optionally substituted by aryl, linear or branched (C2-C6)alkenyl optionally substituted by aryl, linear or branched (C1-C6)perhaloalkyl, (C3-C7)cycloalkyl, adamantyl, aryl or heteroaryl, R3 represents hydrogen, linear or branched (C1-C6)alkyl or (C3-C7)cycloalkyl, A represents CR4R5 or NR4, R4 represents hydrogen or linear or branched (C1-C6)alkyl,their isomers and also their addition salts with a pharmaceutically acceptable acid or base.Medicaments.